Abstract
4-Aminobutyric acid is an inhibitory neurotransmitter involved in the control of neuronal activity in the mammalian central nervous system. There is considerable direct and indirect evidence that impaired activity of GABAmediated inhibitory synapses may be an important causative factor in experimental and clinical seizure disorders. This review is focused on the recent development of compounds which can influence GABA neurotransmission by affecting the GABA receptors, the plasma-membrane GABA transporters (GATs) and catabolic enzyme GABA-transaminase (GABAT). These compounds have been primarily investigated in relation to epilepsy, but it has also been found that a decrease in GABA neurotransmission appears to be involved in the aetiology of several neurological disorders such as insomnia, spasticity, neuropathic pain, anxiety and other mental disorders.
Keywords: GABA, GABA uptake inhibitors, GABAA receptor ligands, GABAB receptor ligands, GABAC receptor ligands, GABA aminotransferaseinhibitors.
Current Medicinal Chemistry
Title:GABA System as a Target for New Drugs
Volume: 21 Issue: 28
Author(s): P. Kowalczyk and K. Kulig
Affiliation:
Keywords: GABA, GABA uptake inhibitors, GABAA receptor ligands, GABAB receptor ligands, GABAC receptor ligands, GABA aminotransferaseinhibitors.
Abstract: 4-Aminobutyric acid is an inhibitory neurotransmitter involved in the control of neuronal activity in the mammalian central nervous system. There is considerable direct and indirect evidence that impaired activity of GABAmediated inhibitory synapses may be an important causative factor in experimental and clinical seizure disorders. This review is focused on the recent development of compounds which can influence GABA neurotransmission by affecting the GABA receptors, the plasma-membrane GABA transporters (GATs) and catabolic enzyme GABA-transaminase (GABAT). These compounds have been primarily investigated in relation to epilepsy, but it has also been found that a decrease in GABA neurotransmission appears to be involved in the aetiology of several neurological disorders such as insomnia, spasticity, neuropathic pain, anxiety and other mental disorders.
Export Options
About this article
Cite this article as:
Kowalczyk P. and Kulig K., GABA System as a Target for New Drugs, Current Medicinal Chemistry 2014; 21 (28) . https://dx.doi.org/10.2174/0929867321666140601202158
DOI https://dx.doi.org/10.2174/0929867321666140601202158 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Metabotropic Glutamate Receptor 5 in Down's Syndrome Hippocampus During Development: Increased Expression in Astrocytes
Current Alzheimer Research Application of Polymeric Nanoparticles for CNS Targeted Zinc Delivery In Vivo
CNS & Neurological Disorders - Drug Targets Defining the Cough Spectrum and Reviewing the Evidence for Treating Non-Specific Cough in Children
Current Pediatric Reviews Editorial (Thematic Issue: Neurology and Genetics: How Molecular Biology is Changing the Neurological Thoughts?)
Current Molecular Medicine Treatment Options in Alzheimer´s Disease: The GABA Story
Current Pharmaceutical Design Editorial [ Neuropeptide Y Receptors as Targets in Drug Discovery Guest Editor: Ambikaipakan Balasubramaniam ]
Current Topics in Medicinal Chemistry Postpartum Psychiatric Disorders: What Do We Know And Where Do We Go?
Current Psychiatry Reviews Recent Multiple Transition Metal Catalysed Single-Pot Reactions
Current Organic Synthesis TRPV1 Channel: A Potential Drug Target for Treating Epilepsy
Current Neuropharmacology Targeting Neuronal Nicotinic Receptors: a Path to New Therapies
Current Drug Targets - CNS & Neurological Disorders Vital Elements of the Wnt-Frizzled Signaling Pathway in the Nervous System
Current Neurovascular Research MtDNA As a Cancer Marker: A Finally Closed Chapter?
Current Genomics Non-canonical Molecular Targets for Novel Analgesics: Intracellular Calcium and HCN Channels
Current Neuropharmacology Biosafety of Recombinant Adeno-associated Virus Vectors
Current Gene Therapy Ring Finger Ubiquitin Protein Ligases and Their Implication to the Pathogenesis of Human Diseases
Current Pharmaceutical Design Neuro-Transmitters in the Central Nervous System & their Implication in Learning and Memory Processes
Current Medicinal Chemistry Feature Extraction, Risky Classifications and Fault Diagnosis on Rolling Bearings of EEG Signals Denoised using Stationary Wavelet Transform of Patient Monitoring and IoT
Current Medical Imaging Knowledge of Pharmacists about Anti-epileptic Drugs in a Developing Country
Current Drug Safety Diabetes, Diabetic Complications, and Phosphate Toxicity: A Scoping Review
Current Diabetes Reviews PET Imaging of Opioid Receptors in Pain: Progress and New Directions
Current Pharmaceutical Design